A Clinical Study of Topical 2% Dorzolamide(Trusopt) as Adjunctive Therapy.
- Author:
Jong Joon LEE
1
;
Jin CHUNG
;
Nam Ho BAEK
Author Information
1. Department of Ophthalmology, Capital Armed Forces General Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Dorzolamide;
Glaucoma;
IOP;
Ocular hypertension;
Side effects
- MeSH:
Blood Pressure;
Burns;
Follow-Up Studies;
Glaucoma;
Heart Rate;
Humans;
Ocular Hypertension;
Sensation;
Tears
- From:Journal of the Korean Ophthalmological Society
1997;38(3):443-449
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We investigated the intraocular pressure(IOP) lowering effect and side effects of 2% dorzolamide(Trusopt) as adjunctive therapy in 18 eyes of 11 glaucoma patients and 10 eyes of 10 normal subjects. For those patients who have taken beta-blocker at least 2 weeks in glaucoma or ocular hypertension, we measured IOP before dorzolamide start and after dorzolamide instillation, every 2 hours from 10 AM to 4 PM for 3 weeks and evaluated the side effects. In normal subjects, we Measured the same method of IOP for 2 weeks and evaluated the side effects. In patients with glaucoma or ocular hypertension, mean IOP was lowered 4.4 mmHg after 2% dorzolamide instillation(P<0.01). There was no change in pulse rate, blood pressure and corneal sensitivity before and after instillation. There was no significant IOP lowering effect on normal subjects(p>0.05). The common side effects were bitter taste, burning sensation, redness, tearing and dryness. Above these results, we think 2% dorzolamide is effective as adjunctive therapy in glaucoma and more follow-up and treatment is needed to establish the fact.
